Arvinas, Inc. vs Johnson & Johnson — Stock Comparison
Q·Score Breakdown
5
Bearish
Overall
7.1
Bullish
Quality
Health
Growth
Valuation
Sentiment
ARVN
Clean balance sheet with low leverage (0.0× debt-to-equity).
⚠ currently unprofitable (-31% margin).
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
HOLD
Target $14.88 (+41.5%)
16 analysts
BUY
Target $252.42 (+11.1%)
24 analysts
Fundamentals
ARVN
JNJ
—
Trailing P/E
26.3×
-3.0×
Forward P/E
17.9×
-30.8%
Profit Margin
21.8%
100.0%
Gross Margin
68.0%
-16.2%
ROE
26.4%
-84.0%
Revenue Growth
9.9%
—
Earnings Growth
-52.9%
1.98
Beta
0.33
—
Price / Book
—
$672M
Market Cap
$546.9B
$6 – $15
52-Week Range
$146 – $252
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →